PubMed · 13655053
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
B S WOLF, D BRYK. Fabella arthritic changes.. https://pubmed.ncbi.nlm.nih.gov/13655053/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Patients with hereditary haemochromatosis are at risk for significant morbidity from iron overload as well as reduced life-expectancy once cirrhosis is established. Although inexpensive, sensitive screening tests and effective therapy are available, there is continued debate regarding the utility of screening for this condition because of recent data suggesting that the homozygous haemochromatosis mutation (C282Y) is associated with low penetrance and mild expressivity when identified in population screening studies. In this review, we examine the published data related to general population screening for haemochromatosis, as well as the evidence for screening selected 'high-risk' populations. We also suggest possible screening strategies based on the available evidence.
Arthritis is the leading cause of disability in the United States, and its prevalence is expected to increase as the U.S. population ages. State-specific estimates of the prevalence of this condition are key to planning health services and programs to prevent arthritis-related disability and to track progress toward meeting national health objectives for 2010 (objectives 2.1-2.8). In 2002, new questions about arthritis were released as an optional module of the Behavioral Risk Factor Surveillance System (BRFSS), and 30 states elected to use the module. This report summarizes results from the 2002 BRFSS on prevalence of doctor-diagnosed arthritis and possible arthritis. The findings indicate that the estimated prevalence of doctor-diagnosed arthritis among adults in the 30 states ranged from 17.8% to 35.8%, and the prevalence of possible arthritis ranged from 10.3% to 21.3%. Increased intervention efforts, including early diagnosis and appropriate clinical and self-management (e.g., physical activity, education, and maintaining appropriate weight), are needed to reduce the impact of arthritis.
The medical and societal impact of arthritis and other rheumatic conditions (AORC) has been characterized with respect to disability, ambulatory care, hospitalization, and economic burden. CDC's estimates of the national and state-specific costs of AORC in the United States in 1997 have been published previously. However, CDC has re-estimated indirect costs by enhancing the statistical methods. This report summarizes the results of that analysis, which indicated that indirect costs were 30.1 billion dollars less than previously estimated. The total cost of AORC in the United States in 1997 was 86.2 billion dollars (including 51.1 billion dollars in direct costs and 35.1 billion dollars in indirect costs), approximately 1% of the U.S. gross domestic product. Total costs attributable to AORC by state ranged from 121 million dollars in Wyoming to 8.4 billion dollars in California. Although indirect costs were lower than estimated previously, costs for arthritis remain high and underscore the need for better interventions to reduce the economic burden of arthritis.